| Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma PJ Maxwell, J Coulter, SM Walker, M McKechnie, J Neisen, N McCabe, ... European urology 64 (2), 177-188, 2013 | 95 | 2013 |
| CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity N Montgomery, A Hill, S McFarlane, J Neisen, A O'Grady, S Conlon, ... Breast Cancer Research 14, 1-19, 2012 | 90 | 2012 |
| Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells PJ Maxwell, J Neisen, J Messenger, DJJ Waugh Oncotarget 5 (13), 4895, 2014 | 86 | 2014 |
| Ex vivo expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function RJ Medina, CL O'neill, TM O'Doherty, SEJ Chambers, J Guduric-Fuchs, ... Stem Cells 31 (8), 1657-1668, 2013 | 75 | 2013 |
| PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy CWD Armstrong, PJ Maxwell, CW Ong, KM Redmond, C McCann, ... Oncotarget 7 (7), 7885, 2016 | 37 | 2016 |
| A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR) J Patel, A Beishuizen, XB Ruiz, H Boughanmi, A Cahn, GJ Criner, K Davy, ... medRxiv, 2021.04. 14.21255475, 2021 | 28 | 2021 |
| Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis … SJW Shoop-Worrall, KL Hyrich, LR Wedderburn, W Thomson, N Geifman, ... The Lancet Rheumatology 3 (2), e111-e121, 2021 | 25 | 2021 |
| A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR) J Patel, D Bass, A Beishuizen, XB Ruiz, H Boughanmi, A Cahn, ... European Respiratory Journal 61 (2), 2023 | 17 | 2023 |
| Mathematical modelling of alternative pathway of complement system S Bakshi, F Cunningham, EM Nichols, M Biedzka-Sarek, J Neisen, ... Bulletin of mathematical biology 82, 1-32, 2020 | 11 | 2020 |
| Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies L Bansal, EM Nichols, DP Howsmon, J Neisen, CM Bessant, ... Frontiers in Pharmacology, 2022 | 5 | 2022 |
| Interpretable histopathology-based prediction of disease relevant features in Inflammatory Bowel Disease biopsies using weakly-supervised deep learning R Mokhtari, A Hamidinekoo, D Sutton, A Lewis, B Angermann, ... arXiv preprint arXiv:2303.12095, 2023 | 3 | 2023 |
| Development and application of a Quantitative Systems Pharmacology (QSP) model of complement pathway to evaluate treatments for autoimmune diseases L Bansal, J Neisen, EM Nichols, V Damian J. Pharmacokinet Pharmacodyn 44, S91-S92, 2017 | 2 | 2017 |
| Abstract A49: Cabozantinib attenuates CXCL8-driven macrophage-dependent migration and invasion of PTEN-deficient prostate cancer JL Neisen, N McCabe, RD Kennedy, DJJ Waugh Cancer Research 75 (1_Supplement), A49-A49, 2015 | 2 | 2015 |
| DOP06 deep characterization of IL-23 pathway in different gut segments and associated plasma biomarkers in inflammatory bowel disease J Cairns, S Monkley, S Tian, B Angermann, Z Liu, L Öberg, D Muthas, ... Journal of Crohn's and Colitis 17 (Supplement_1), i64-i67, 2023 | 1 | 2023 |
| P879 Clinical significance of plasma interleukin-22 as a biomarker of inflammation in patients with Crohn’s disease and ulcerative colitis C Cabrera-Moksnes, D Fernandez-Llaneza, J Neisen, BR Angermann, ... Journal of Crohn's and Colitis 17 (Supplement_1), i996-i997, 2023 | 1 | 2023 |
| IL-7 Binding Proteins and Their Use in Medical Therapy G Bouma, ET Coulstock, D Dixon, S Hopley, AP Lewis, JL Neisen US Patent App. 18/460,944, 2024 | | 2024 |
| Artificial Intelligence to predict interleukin-23 signalling activity from H&E stained whole slide images of Inflammatory Bowel Disease T Qaiser, A Hamidinekoo, S Daniel, I Zhang, M Kekic, A Lewis, ... JOURNAL OF CROHNS & COLITIS 18, I453-I453, 2024 | | 2024 |
| P153 Artificial Intelligence to predict interleukin-23 signalling activity from H&E stained whole slide images of Inflammatory Bowel Disease T Qaiser, A Hamidinekoo, S Daniel, I Zhang, M Kekic, A Lewis, ... Journal of Crohn's and Colitis 18 (Supplement_1), i458-i458, 2024 | | 2024 |
| Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease S Danese, A Beaton, EA Duncan, AK Mercier, J Neisen, H Seth, ... BMC gastroenterology 23 (1), 451, 2023 | | 2023 |
| IL-7 binding proteins and their use in medical therapy G Bouma, ET Coulstock, D Dixon, S Hopley, AP Lewis, JL Neisen US Patent 11,802,150, 2023 | | 2023 |
